---
title: "AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295669971.md"
description: "CEO Thomas K. Equels has urged for a proactive assessment of wide-ranging antiviral defenses before the emergence of new viral dangers. Equels emphasizes the need for preparedness in the face of potential threats."
datetime: "2026-08-12T12:46:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295669971.md)
  - [en](https://longbridge.com/en/news/295669971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295669971.md)
generator: "portal-rs"
---

# AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

CEO Thomas K. Equels has urged for a proactive assessment of wide-ranging antiviral defenses before the emergence of new viral dangers. Equels emphasizes the need for preparedness in the face of potential threats.

### Related Stocks

- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [AIM ImmunoTech advances Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi in pancreatic cancer](https://longbridge.com/en/news/298463441.md)
- [Independent Director of Atara Biotherapeutics Picks Up 272% More Stock](https://longbridge.com/en/news/298137689.md)
- [BKYI: Biometric IAM platform accelerates growth amid regulatory demand and global deployments](https://longbridge.com/en/news/298369687.md)
- [08:00 ETMinistry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio](https://longbridge.com/en/news/298210868.md)
- [RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results](https://longbridge.com/en/news/298139566.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**